New International Registration for Medical Device Flogorex Med Spray
Gruppo Farmaimpresa continues its international expansion with the registration of Flogorex Med Spray with the Moroccan Agency for Medicines and Health Products.
Obtaining this registration allows the commercialization of Flogorex Med Spray in the Moroccan market and represents a further step in the international development strategy of Farmaimpresa medical devices.
The Moroccan market represents a strategic opportunity
In recent years, Morocco has consolidated its role as one of the main healthcare markets in North Africa, characterized by growing demand for innovative health products and a progressive strengthening of regulatory standards.
For international manufacturers, obtaining the registration of a medical device represents a fundamental requirement for access to the local market and for subsequent distribution through qualified operators.
The registration of Flogorex Med Spray confirms the product’s compliance with the requirements set by the competent authorities and contributes to expanding the international presence of Farmaimpresa’s medical device portfolio.
FT.CE.155: medical device for osteo-articular inflammation
Flogorex Med Spray is a medical device developed to support the treatment of inflammatory processes affecting the musculoskeletal system and soft tissues.
The product is characterized by an anti-inflammatory and anti-edematous action aimed at contributing to the reduction of symptoms such as pain, burning, and edema associated with inflammatory processes.
The main areas of application include:
- osteo-articular inflammation;
- soft tissue trauma;
- tendinitis;
- contusions;
- post-operative reactions;
- painful joint manifestations;
- inflammatory processes associated with edema.
A formulation developed for musculoskeletal well-being
The formulation of Flogorex Med Spray combines selected ingredients to support the well-being of the osteo-articular system and contribute to the control of local inflammatory processes.
Among the components in the formulation are plant extracts and functional substances traditionally used in the support of conditions characterized by pain and inflammation, including Harpagophytum procumbens, Arnica montana, Bromelain, Menthol, Camphor, and selected essential oils.
The extract of Harpagophytum procumbens is associated with support for joint mobility and the control of inflammatory mediators, while Arnica montana is traditionally used for its anti-traumatic and anti-edematous properties.
International distribution and private label opportunities
The registration in Morocco further expands the commercial opportunities for Flogorex Med Spray and allows local partners to access a medical device already authorized for the national market.
Thanks to its position in the field of osteo-articular inflammation and musculoskeletal well-being, Flogorex Med Spray represents an attractive solution for distributors, importers, and healthcare operators looking for innovative products ready for commercialization.
The product is available both for distribution projects and in private label mode, offering commercial partners the opportunity to develop new business opportunities in their respective markets.
FT.CE.155 strengthens Farmaimpresa’s international presence
Obtaining the registration of Flogorex Med Spray in Morocco represents a further achievement in Farmaimpresa’s internationalization journey and confirms the company’s ability to develop and register medical devices that comply with the regulatory requirements of international markets.
This milestone contributes to consolidating the group’s presence in the medical device sector and expanding growth opportunities in high-potential healthcare markets.
Interested in distributing FT.CE.155 in your market?
Flogorex Med Spray is available for international distribution and private label projects.
To receive technical documentation, regulatory information, or to explore commercial collaboration opportunities, contact the Farmaimpresa team.
